X-82 + ranibizumab

**X-82 + ranibizumab** is an investigational combination therapy evaluated for the treatment of neovascular (wet) age-related macular degeneration (AMD). X-82 is an oral small-molecule tyrosine kinase inhibitor derived from sunitinib that selectively inhibits multiple receptor tyrosine kinases, primarily those of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Ranibizumab is a recombinant, humanized monoclonal antibody fragment (Fab) that inhibits VEGF-A, and is administered by intravitreal injection. The rationale for this combination is dual pathway inhibition: X-82 blocks angiogenic signaling at the VEGF and PDGF receptors systemically, potentially reducing the frequency of intravitreal injections required, while ranibizumab locally neutralizes VEGF-A. The combination has shown non-inferiority in visual acuity outcomes compared to anti-VEGF monotherapy while potentially decreasing the number of required intravitreal injections. However, tolerability and safety concerns were observed for X-82 in clinical trials[3][1][4][5][6].

Brand names

Lucentis

Other names

sunitinib-derived VEGF/PDGF inhibitor + ranibizumab